London- Alsharq Tribune- Mohamed Otaify
AstraZeneca is no longer pursuing plans for a 450 million pound ($558.32 million) vaccine manufacturing plant in Speke, Liverpool, a company spokesperson said on Friday.
"Following discussions with the current government, we are no longer pursuing our planned investment at Speke," an AstraZeneca spokesperson said in a statement.
"Several factors have influenced this decision including the timing and reduction of the final offer compared to the previous government's proposal. "The site will continue to produce and supply our flu vaccine, for patients in the UK and around the world.”
